Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Bazhenova L, Hodgson J, Camidge D, Langer C, Huber R, Kim D, Reckamp K, Ahn M, Tan D, Patel J, Vincent S, Li C, Humphries M, Zhang P, Rivera V, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clinical Lung Cancer 2025 PMID: 40582920, DOI: 10.1016/j.cllc.2025.05.016.Peer-Reviewed Original ResearchObjective response rateProgression-free survivalMedian progression-free survivalALK-positive NSCLCCirculating tumor DNAALK mutationsALK fusionsMutation statusALK-positive non-small-cell lung cancerNon-small-cell lung cancerPlasma circulating tumor DNAActivity of brigatinibBaseline tumor samplesSecondary ALK mutationsMechanisms of resistanceALK alterationsALK amplificationALK inhibitorsPhase 1/2Preclinical activityTumor DNABrigatinibTumor samplesLung cancerTumor tissues
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply